UA105786C2 - Адитивні солі амінів, що містять гідроксильні і/або карбоксильні групи, з похідними амінонікотинової кислоти як інгібітори dhodh - Google Patents

Адитивні солі амінів, що містять гідроксильні і/або карбоксильні групи, з похідними амінонікотинової кислоти як інгібітори dhodh

Info

Publication number
UA105786C2
UA105786C2 UAA201111802A UAA201111802A UA105786C2 UA 105786 C2 UA105786 C2 UA 105786C2 UA A201111802 A UAA201111802 A UA A201111802A UA A201111802 A UAA201111802 A UA A201111802A UA 105786 C2 UA105786 C2 UA 105786C2
Authority
UA
Ukraine
Prior art keywords
groups
addition salts
acid derivatives
nicotinic acid
innhibitors
Prior art date
Application number
UAA201111802A
Other languages
English (en)
Russian (ru)
Inventor
Гарсія Хуан Баутіста Перес
Каррера Франсеск Каррера
Мартін Дігна Хосе Гарсія
Бернардіні Марія Кармен Бош
Original Assignee
Алміралл, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Алміралл, С.А. filed Critical Алміралл, С.А.
Publication of UA105786C2 publication Critical patent/UA105786C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Даний винахід належить до нових водорозчинних фармацевтично прийнятних кристалічних адитивних солей (і) аміну, що містить одну або декілька гідроксильних та/або карбоксильних груп, з (іі) похідними амінонікотинової кислоти формули (І), де R, R, Rі Rнезалежно являють собою групи, вибрані з атомів водню, атомів галогену, C-алкільних груп, які необов'язково можуть бути заміщені 1, 2 або 3 замісниками, вибраними із атомів галогену і гідроксигруп, і C-алкоксигруп, які необов'язково можуть бути заміщені 1, 2 або 3 замісниками, вибраними із атомів галогену і гідроксигруп, і їх фармацевтично прийнятних сольватів.(I)
UAA201111802A 2009-03-13 2010-03-11 Адитивні солі амінів, що містять гідроксильні і/або карбоксильні групи, з похідними амінонікотинової кислоти як інгібітори dhodh UA105786C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382031A EP2228367A1 (en) 2009-03-13 2009-03-13 Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
PCT/EP2010/001550 WO2010102826A1 (en) 2009-03-13 2010-03-11 Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as dhodh inhibitors

Publications (1)

Publication Number Publication Date
UA105786C2 true UA105786C2 (uk) 2014-06-25

Family

ID=40677683

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201111802A UA105786C2 (uk) 2009-03-13 2010-03-11 Адитивні солі амінів, що містять гідроксильні і/або карбоксильні групи, з похідними амінонікотинової кислоти як інгібітори dhodh

Country Status (35)

Country Link
US (1) US20120014918A1 (uk)
EP (2) EP2228367A1 (uk)
JP (1) JP5674685B2 (uk)
KR (1) KR101674699B1 (uk)
CN (1) CN102348689B (uk)
AR (1) AR075738A1 (uk)
AU (1) AU2010223528B2 (uk)
BR (1) BRPI1006766B8 (uk)
CA (1) CA2754804C (uk)
CL (1) CL2011002216A1 (uk)
CO (1) CO6420337A2 (uk)
CY (1) CY1114418T1 (uk)
DK (1) DK2406225T3 (uk)
EA (1) EA022350B1 (uk)
EC (1) ECSP11011365A (uk)
ES (1) ES2428746T3 (uk)
HK (1) HK1162487A1 (uk)
HR (1) HRP20130851T1 (uk)
IL (1) IL214519A (uk)
ME (1) ME01564B (uk)
MX (1) MX2011009146A (uk)
MY (1) MY155140A (uk)
NZ (1) NZ594493A (uk)
PE (1) PE20120171A1 (uk)
PL (1) PL2406225T3 (uk)
PT (1) PT2406225E (uk)
RS (1) RS52949B (uk)
SG (1) SG173823A1 (uk)
SI (1) SI2406225T1 (uk)
SM (1) SMT201300104B (uk)
TW (1) TWI428127B (uk)
UA (1) UA105786C2 (uk)
UY (1) UY32467A (uk)
WO (1) WO2010102826A1 (uk)
ZA (1) ZA201105744B (uk)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) * 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
EP2444088A1 (en) * 2010-10-22 2012-04-25 Almirall, S.A. Amino derivatives for the treatment of proliferative skin disorders
EP2594271A1 (en) * 2011-11-21 2013-05-22 Almirall, S.A. 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid for the treatment of psoriasis.
KR101251851B1 (ko) 2011-11-30 2013-04-10 현대자동차주식회사 Ｉｓｇ 시스템 및 이의 제어방법
TW201350467A (zh) * 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) * 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
WO2014167585A1 (en) * 2013-04-12 2014-10-16 Actavis Group Ptc Ehf. Pemetrexed formulation
WO2018136010A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
WO2018157842A1 (zh) * 2017-03-02 2018-09-07 中国科学院上海药物研究所 2-(取代苯氨基)苯甲酸类fto抑制剂治疗白血病的用途
US20210379070A1 (en) 2018-10-09 2021-12-09 Aslan Pharmaceuticals Pte Ltd Malonate salt of varlitinib
SG11202106526UA (en) * 2018-12-21 2021-07-29 Les Laboratoires Servier Sas Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof
WO2022081095A1 (en) * 2020-10-15 2022-04-21 Aslan Pharmaceuticals Pte. Ltd. Treatment of autoimmune diseases with a dihydroorotate hehydrogenase (dhodh) inhibitor
CN114907267A (zh) * 2021-02-08 2022-08-16 中国科学院上海药物研究所 用于抗肿瘤的药物组合

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839344A (en) * 1973-03-28 1974-10-01 Schering Corp N-methyl d-glucamine salt of 2(2'-methyl-3'-trifluoromethylanilino)nicotinic acid
GB9804343D0 (en) 1998-02-27 1998-04-22 Univ Cardiff Chemical compounds
GEP20053423B (en) * 1999-06-10 2005-01-25 Warner Lambert Co Method of Inhibiting Amyloid Protein Aggregation and Method for Imaging of Amyloid Deposits
EP1935416A3 (en) 2001-04-05 2008-10-22 Aventis Pharma Inc (Z) -2-cyano-3-hydroxybut-2-enoic acid (4'-trifluoromethylphenyl) amide for the treatment of multiple sclerosis
WO2003006424A1 (en) * 2001-07-10 2003-01-23 4Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
JP2004099586A (ja) * 2002-05-21 2004-04-02 Sumitomo Pharmaceut Co Ltd ジヒドロオロテートデヒドロゲナーゼ阻害剤
US7071355B2 (en) 2002-12-23 2006-07-04 4 Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2004056747A1 (en) 2002-12-23 2004-07-08 4Sc Ag Dhodh-inhibitors and method for their identification
CN1993125A (zh) 2004-05-21 2007-07-04 Uab研究基金会 涉及嘧啶合成抑制剂的组合物和方法
WO2006022442A1 (ja) 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
EP1804782A1 (en) 2004-10-19 2007-07-11 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
JP2007015952A (ja) * 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
ES2303758B1 (es) 2006-02-20 2009-08-13 Laboratorios Almirall S.A. Nuevos derivados de piridin-3-amina.
ES2301380B1 (es) 2006-08-09 2009-06-08 Laboratorios Almirall S.A. Nuevos derivados de 1,7-naftiridina.
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) * 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico

Also Published As

Publication number Publication date
NZ594493A (en) 2013-11-29
US20120014918A1 (en) 2012-01-19
EA022350B1 (ru) 2015-12-30
EP2406225A1 (en) 2012-01-18
ES2428746T3 (es) 2013-11-11
BRPI1006766B8 (pt) 2021-05-25
PE20120171A1 (es) 2012-03-01
CA2754804A1 (en) 2010-09-16
KR101674699B1 (ko) 2016-11-09
EP2406225B1 (en) 2013-06-26
WO2010102826A1 (en) 2010-09-16
CO6420337A2 (es) 2012-04-16
HK1162487A1 (en) 2012-08-31
EA201101297A1 (ru) 2012-04-30
ECSP11011365A (es) 2011-10-31
RS52949B (en) 2014-02-28
SI2406225T1 (sl) 2013-10-30
PL2406225T3 (pl) 2013-12-31
SMT201300104B (it) 2013-11-08
PT2406225E (pt) 2013-09-19
ME01564B (me) 2014-09-20
CL2011002216A1 (es) 2012-03-09
KR20110126694A (ko) 2011-11-23
CY1114418T1 (el) 2016-08-31
CN102348689A (zh) 2012-02-08
JP2012520252A (ja) 2012-09-06
JP5674685B2 (ja) 2015-02-25
ZA201105744B (en) 2012-04-25
IL214519A0 (en) 2011-09-27
SG173823A1 (en) 2011-09-29
AU2010223528B2 (en) 2017-02-16
EP2228367A1 (en) 2010-09-15
AR075738A1 (es) 2011-04-20
CN102348689B (zh) 2014-05-14
AU2010223528A1 (en) 2011-08-25
TW201034669A (en) 2010-10-01
UY32467A (es) 2010-05-31
HRP20130851T1 (hr) 2013-10-25
BRPI1006766B1 (pt) 2021-03-23
MY155140A (en) 2015-09-15
CA2754804C (en) 2018-07-24
MX2011009146A (es) 2011-09-15
DK2406225T3 (da) 2013-09-30
TWI428127B (zh) 2014-03-01
IL214519A (en) 2015-03-31

Similar Documents

Publication Publication Date Title
UA105786C2 (uk) Адитивні солі амінів, що містять гідроксильні і/або карбоксильні групи, з похідними амінонікотинової кислоти як інгібітори dhodh
TW200833675A (en) Nicotinamide derivatives
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MX2010003155A (es) Derivados de ciclopropil aril amida y uso de los mismos.
MX2012002011A (es) Composicion farmaceutica que contiene derivado de quinolina.
UA102251C2 (uk) Похідні амінодигідротіазину як інгібітори васе для лікування хвороби альцгеймера
WO2010007046A3 (en) Heteroaryl derivatives as dgat1 inhibitors
NZ712352A (en) Novel inhibitors of glutaminyl cyclase
UA109525C2 (xx) Алкіламідна сполука і її застосування
UA97821C2 (en) Cyclized derivatives as eg-5 inhibitors
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
MX2010008362A (es) Derivados de heteroarilamida diazepinopirimidona sustituidos.
MX2010008360A (es) Derivados de oxazepinopirimidona heteroarilamida sustituidos.
MX2010013939A (es) Derivados de n-oxido pirazina sustituidos.
EA200700360A1 (ru) Новые производные амида гетероциклической карбоновой кислоты
MX2013007938A (es) Compuesto biciclico novedoso o sal del mismo.
MY150774A (en) Isoquinoline derivative
MX359069B (es) Sal y formas cristalinas de inhibidor de quinasa tipo polo-4.
MX341341B (es) Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90).
MX2012004835A (es) Derivados de espirolactama y usos de los mismos.
MX355654B (es) Derivado de paroxetina.
JO2851B1 (en) 3-benzofuranil-indole-2-one-3-substituted acetamidopiprazine derivatives, preparations thereof and therapeutic use thereof.
UA104302C2 (uk) Похідні морфін-6-глюкуроніду, їх отримання і їх застосування в терапії
MX2014008856A (es) Derivados de imidazolilcetona como inhibidores de aldosterona sintasa.
TN2010000608A1 (en) Heteroaryl derivatives as dgat1 inhibitors